Cell Medica strengthens team with key appointment to senior management
Cell Medica has announced that is has appointed four key staff to drive forwards the Company’s activities in the commercialisation of cell therapy treatments. The appointments will enable the Company to achieve scale up of its cell manufacturing operations, increase its clinical development capabilities and create a US presence with the appointment of a Head of US Operations. The new members of the management team include:
Dr Rainer Knaus, Senior Vice President - Rainer has over ten years experience in the GMP manufacturing of cell therapies and managed the commercial launch of the first stem cell product in Germany. Rainer is overseeing European activities including manufacturing, product development and regulatory requirements.
Mike Ramsay, Head of US Operations - Mike joins Cell Medica from his position as Senior Vice President of Operations at Cell Genesys. Mike has over 20 years experience in the US biotech industry and is leading the Company’s US business activities. Mike will establish the US business infrastructure which includes R&D partnerships with leading academic research institutions.
Karen Hodgkin, Head of Clinical Development – Karen has 25 years experience in clinical trials management across a range of therapeutic areas. Karen is managing the Company’s confirmatory clinical trial currently running across 14 major hospitals in the UK.
Tina Crombie, Head of Business Administration – Tina’s experience in IP management, project management and business administration includes previous positions in academic, public and commercial science-based organizations.
To fund these developments and its business towards commercialisation, Cell Medica has recently secured an additional $5.4 million in equity investment and grant funding. The new equity totalled US$ 3.2m with Imperial Innovations as the lead investor in combination with private investors. Grant funding of US$ 2.2m has also been won through awards from the UK Technology Strategy Board. Cell Medica led the collaborative bid under the High Value Manufacturing program, in conjunction with University College London and eXmoor Pharma Concepts Ltd. The research project is aimed at designing and validating a new state-of-the-art manufacturing system which will significantly reduce the unit cost of producing individualised cell therapies. The Company received a second grant from the Technology Strategy Board to support the development of a novel therapy to treat life-threatening adenovirus infections in children following bone marrow transplants, and is planning a clinical trial to test this new therapeutic approach during 2010.
Other news from the department people
Most read news
More news from our other portals
Last viewed contents
From exposomics to phytotoxins: Safe foodstuffs in the focus of analytica 2018
A new era of mitochondrial genome editing has begun - Scientists successfully achieve A to G base conversion, the final missing piece of the puzzle in gene-editing technology
Images of NMDA receptors help explain how they are affected by zinc and a drug
Selvita Appoints Piotr Prelich as a Vice President of Sales and Marketing
Evotec to collaborate with Ology Bioservices on antibodies against Coronavirus - Antibodies were generated from convalescing COVID-19 patients
European Regulatory Committee Recommends Orphan Drug Status for GPC Biotech's Anticancer Monoclonal Antibody
More efficient biosolar cells modelled on nature - By combining light-collecting and photosynthesis proteins of different types, more energy can be produced
Artificial enzymes convert solar energy into hydrogen gas
A vaccine alternative protects mice against malaria - Vectored immunoprophylaxis injection triggers creation of antibodies that prevent malaria in 70 percent of mice
KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform - AstriVax to develop novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection
